Morganella morganii

Morganella morganii
bacteria growth in red on white background
Scientific classification
Domain:
Bacteria
Phylum:
Proteobacteria
Class:
Gammaproteobacteria
Order:
Enterobacterales
Family:
Morganellaceae
Genus:
Morganella

Fulton, 1943
Species:
M. morganii
Binomial name
Morganella morganii
Winslow et al., 1919
Fulton, 1943
Brenner et al., 1978[1]
Subspecies

M. m. morganii
M. m. sibonii

Synonyms
  • Proteus morganii
    Winslow et al., 1919
    Yale, 1939    [1]

Morganella morganii is a species of Gram-negative bacteria.[2] It has a commensal relationship within the intestinal tracts of humans, mammals, and reptiles as normal flora.[2] Although M. morganii has a wide distribution, it is considered an uncommon cause of community-acquired infection and it is most often encountered in postoperative and other nosocomial infections such as urinary tract infections.[3]

Historical identification and systematics

Morganella morganii was first described by a British bacteriologist H. de R. Morgan in 1906 as Morgan's bacillus. Morgan isolated the bacterium from stools of infants who were noted to have had "summer diarrhea".[4] Later in 1919, Winslow et al. named Morgan's bacillus, Bacillus morganii. In 1936, though, Rauss renamed B. morganii as Proteus morganii. Fulton, in 1943, showed that B. columbensis and P. morganii were the same and defined the genus Morganella, due to the DNA-DNA hybridization.[5] M. morganii has two subspecies – M. m. morganii and M. m. columbensis.[6] However, in 1962, a review article by Ewing reported that M. columbensis had been re-identified as Escherichia coli, thereby removing that organism from the genus Morganella.[6]

Microbiology

M. morganii grown on blood agar

Morganella morganii is facultatively anaerobic and oxidase-negative. Its colonies appear off-white and opaque in color, when grown on agar plates.[7] M. morganii cells are straight rods, about 0.6–0.7 μm in diameter and 1.0–1.7 μm in length. This organism moves by way of peritrichous flagella, but some strains do not form flagella at 30 °C.[8]

M. morganii can produce the enzyme catalase, so is able to convert hydrogen peroxide to water and oxygen. This is a common enzyme found in most living organisms. In addition, it is indole test-positive meaning that this organism can split tryptophan to indole, pyruvate, and ammonia. Methyl red tests positive in M. morganii, an indicator dye that turns red due to the bacterium's acid production during fermentation.[7] Although a rare human pathogen, M. morganii has been reported as a cause of urinary tract infections, nosocomial surgical wound infections, peritonitis, central nervous system infection, endophthalmitis, pneumonia, chorioamnionitis, neonatal sepsis, pyomyositis, necrotizing fasciitis, and arthritis. Numerous cases of nosocomial infection have been described, usually as postsurgical wound infections or urinary tract infections. Patients in whom bacteremia develops are typically immunocompromised, diabetic, or elderly, or have at least one serious underlying disease.

Role of bacteria

M. morganii consists of two species: M. morganii and M. sibonii. M. morganii has been regarded as a normally harmless opportunistic pathogen, but some strains carry "antibiotic-resistant plasmids" and have been associated with nosocomial outbreaks of infections.[9] Several reports indicate M. morganii causes sepsis, ecthyma, endophthalmitis, and chorioamnionitis, and more commonly urinary tract infections, soft tissue infections, septic arthritis, meningitis, and bacteremia, in the latter 2 cases with frequent fatal consequences.[10]

In a rare case published in 2003, a patient presented with bilateral necrosis of both upper and lower eyelids. Upon microbial analysis, the areas were shown to have heavy growth of M. morganii.[11]

Treatment and antibiotic resistance

Treatment of M. morganii infections may include:

  • Ticarcillin
  • Piperacillin
  • Ciprofloxacin
  • Third-generation and fourth-generation cephalosporins

A study conducted at the University Hospital at Heraklion, Crete, Greece showed a 92% success rate in the use of these antibiotics.[12]

However, some M. morganii strains are resistant to penicillin, ampicillin/sulbactam, oxacillin, first-generation and second-generation cephalosporins, macrolides, lincosamides, fosfomycin, colistin, and polymyxin B.[3] The emergence of highly resistant strains of M. morganii have been associated with use of third-generation cephalosporins.[3]

Polymicrobial infections are most abundantly caused by this microbe which additionally damages the skin, soft tissues, and urogenital tract; these can be cured through use of the aforementioned antibiotics.[12]

References

  1. 1 2 UniProt. Morganella morganii (Proteus morganii)
  2. 1 2 eMedicine. Morganella infections
  3. 1 2 3 "Morganella infections". Medscape. Retrieved 5 December 2012.
  4. ↑ Pulaski, E. J.; Deitz, G. W. (1940). "Morgan's bacillus septicemia". Journal of the American Medical Association. 115 (11): 922. doi:10.1001/jama.1940.72810370001008. ISSN 0002-9955.
  5. ↑ Chen, Yu-Tin; Peng, Hwei-Ling; Shia, Wei-Chung; Hsu, Fang-Rong; Ken, Chuian-Fu; Tsao, Yu-Ming; Chen, Chang-Hua; Liu, Chun-Eng; Hsieh, Ming-Feng; Chen, Huang-Chi; Tang, Chuan-Yi; Ku, Tien-Hsiung (2012). "Whole-genome sequencing and identification of Morganella morganii KT pathogenicity-related genes". BMC Genomics. 13 (Suppl 7): S4. doi:10.1186/1471-2164-13-S7-S4. ISSN 1471-2164. PMC 3521468. PMID 23282187.
  6. 1 2 O'Hara CM, Brenner FW, Miller JM (13 October 2000). "Classification, identification, and clinical significance of Proteus, Providencia, and Morganella". Clinical Microbiology Reviews. 4. 13 (4): 534–546. doi:10.1128/cmr.13.4.534-546.2000. PMC 88947. PMID 11023955.
  7. 1 2 Herrara, Jose. "Morganella morganii". Truman State University Biology. Truman State University. Archived from the original on 13 December 2012. Retrieved 6 December 2012.
  8. ↑ "Morganella morganii". University of Windsor. Retrieved 6 December 2012.
  9. ↑ Senior, W; S. Voros (1990). "Protein profile typing--a new method of typing Morganella morganii strains" (PDF). Journal of Medical Microbiology. 33 (4): 259–264. doi:10.1099/00222615-33-4-259. PMID 1701835. Archived from the original (PDF) on 4 September 2011. Retrieved 6 December 2012.
  10. ↑ Singla, Nidhi; Neelam Kaistha; Neelam Gulati; Jagdish Chander (July–September 2010). "Morganella morganii could be an important intensive care unit pathogen". Indian Journal of Critical Care Medicine. 14 (3): 154–155. doi:10.4103/0972-5229.74176. PMC 3021833. PMID 21253351.
  11. ↑ Shenoy MD; AU Shenoy; AM Rajay; ZH al Mahrooqui (2003). "Necrotic Periorbital Ulceration due to Morganella morganii" (PDF). Asian Journal of Ophthalmology. 1. 5. Archived from the original (PDF) on 2 February 2014. Retrieved 10 December 2012.
  12. 1 2 Falagas, M.E.; P.K. Kavvadia; E. Mantadakis; D.P. Kofteridis; I.A. Bliziotis; E. Saloustros; S. Maraki; G. Samonis (2006). "Morganella morganii infections in General Tertiary Hospital". Clinical and Epidemiology Study. 6 (6): 315–321. doi:10.1007/s15010-006-6682-3. PMID 17180585.

Further reading

  • De, A; Raj, HJ; Maiti, PK (2016). "Biofilm in osteomyelitis caused by a rare pathogen, Morganella morganii: A case report". Journal of Clinical and Diagnostic Research. 10. PMC 4963648 – via Elsevier Science Direct.
  • Emborg, J; Dalgaard, P (2008). "Growth, inactivation and histamine formation of Morganella psychrotolerans and Morganella morganii - development and evaluation of predictive models". International Journal of Food Microbiology. 128: 234–243 – via Elsevier Science Direct.
  • Hu, LT; Nicholson, EB; Jones, BD; Lynch, MJ; Mobley, HLT (1990). "Morganella morganii urease: Purification, characterization, and isolation of gene sequences". Journal of Bacteriology. 172: 3073–3080. PMC 209110 – via Elsevier Science Direct.
  • Lee, IK; Liu, JW (2006). "Clinical characteristics and risk factors for mortality in Morganella morganii bacteremia". Journal of Microbiology, Immunology, and Infection. 39: 328–334 – via Elsevier Science Direct.
  • Liu, H; Zhu, J; Hu, Q; Rao, X (2016). "Clinical characteristics and risk factors for mortality in Morganella morganii bacteremia". International Journal of Infectious Diseases. 50: 10–17 – via Elsevier Science Direct.
  • Özoğul, F (2004). "Production of biogenic amines by Morganella morganii, Klebsíella pneumoniae and Hafnia alvei using a rapid HPLC method". European Food Research and Technology. 219: 465–469 – via Elsevier Science Direct.
  • Parikh, RY; Ramanathan, R; Coloe, PJ; Bhargava, SK; Patole, MS; Shouche, YS; Bansal, V (2011). "Genus-wide physicochemical evidence of extracellular crystalline silver nanoparticles biosynthesis by morganella spp". PLoS ONE. 6. PMC 3119697 – via Elsevier Science Direct.
  • Rojas, L; Vinuesa, T; Tubau, F; Truchero, C; Benz, R; Viñas, M (2006). "Integron presence in a multiresistant Morganella morganii isolate". International Journal of Antimicrobial Agents. 27: 502–512 – via Elsevier Science Direct.</ref>Stock, I; Wiedemann, B (1998). "Identification and natural antibiotic susceptibility of Morganella morganii". Diagnostic Microbiology and Infectious Disease. 30: 153–165 – via Elsevier Science Direct.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.